Chicago Capital LLC Purchases Shares of 4,300 Janux Therapeutics, Inc. (NASDAQ:JANX)

Chicago Capital LLC purchased a new position in Janux Therapeutics, Inc. (NASDAQ:JANX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,300 shares of the company’s stock, valued at approximately $230,000.

Other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. grew its position in Janux Therapeutics by 10.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company’s stock worth $596,000 after buying an additional 1,095 shares in the last quarter. Avanza Fonder AB bought a new stake in shares of Janux Therapeutics during the 4th quarter valued at about $139,000. Franklin Resources Inc. grew its holdings in shares of Janux Therapeutics by 64.5% during the third quarter. Franklin Resources Inc. now owns 18,983 shares of the company’s stock worth $937,000 after purchasing an additional 7,442 shares in the last quarter. Virtu Financial LLC increased its position in shares of Janux Therapeutics by 48.0% in the third quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock worth $339,000 after purchasing an additional 2,419 shares during the last quarter. Finally, Neo Ivy Capital Management purchased a new stake in Janux Therapeutics in the third quarter valued at approximately $940,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Down 3.2 %

NASDAQ:JANX opened at $42.07 on Tuesday. The firm has a market capitalization of $2.21 billion, a P/E ratio of -35.96 and a beta of 3.16. The company has a fifty day moving average of $51.47 and a 200 day moving average of $48.44. Janux Therapeutics, Inc. has a 52 week low of $7.79 and a 52 week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The firm had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. The firm’s revenue for the quarter was down 82.6% compared to the same quarter last year. As a group, analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 13,334 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total value of $731,769.92. Following the completion of the sale, the insider now directly owns 82,139 shares in the company, valued at $4,507,788.32. This trade represents a 13.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO David Alan Campbell sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total value of $300,000.00. Following the transaction, the chief executive officer now owns 293,054 shares in the company, valued at $17,583,240. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 83,334 shares of company stock worth $4,731,520. 29.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on JANX shares. Lifesci Capital raised shares of Janux Therapeutics to a “strong-buy” rating in a report on Friday, December 27th. Cantor Fitzgerald restated an “overweight” rating and set a $200.00 price target on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Stifel Nicolaus lifted their price target on Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. UBS Group assumed coverage on Janux Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $69.00 price objective on the stock. Finally, Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $89.90.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.